RESUMEN
Objective To investigate the effects of anti-parkinsonian drugs on cytokines(IL-6 and TNF-?) produced by PBMC in PD patients. Methods 25 subjects were divided into 3 groups : normal controls(NC),pergolide and Madopar treated PD patients(P+M group),Madopar treated PD patients(M group). PBMC were cultured in the presence of pure RPMI-1640,RPMI-1640 with ConA and RPMI-1640 with pergolide,respectively. The amount of IL-6 and TNF-? in the culture media was measured by enzyme-linked immunosorbent assay (ELISA). Results IL-6 production amount by PBMC when stimulated with ConA was significantly lower in group P+M and M than in group NC( P 0.05). In group P+M,the concentration of TNF-? was significantly higher in the presence of ConA than in the presence of pure RPMI-1640 and in the presence of pergolide( P 0.05). Conclusions The ability of amount by PBMC of PD elderly patients to excrete IL-6 was significantly decreased in the presence of ConA. Pergolide might arise the excretion of IL-6 by PBMC during the treatment process of PD and at the same time does not arise the excretion of TNF-?,which might be neurotoxic.
RESUMEN
Aim To explore the antioxidation of pergolide on rat models of Parkinson disease and its mechanism. Methods Wistar rats were pretreated daily with pergolide(1.0 mg?kg -1,ip),pergolide combined with sulpiride(25 mg?kg -1) or sulpiride alone for 7 days, and then sacrificed by decapitation. The activity of SOD and GSH in striatum was determined. Unilateral Parkinsonian models were made in rest of the rats by stereotaxically injecting 6-OHDA. After two weeks, apomorphine (APO)-induced rotational behavior of each group was compared, and the concentrations of striatal dopamine (DA),dihydroxyphenyl acetic acid(DOPAC) and homovanilic acid(HVA) were determined by high performance liquid chromatography (HPLC). Result Administration of pergolide for 7 days significantly increased the act- ivities of SOD and GSH in the striatum (P
RESUMEN
Objective The clinical efficacy and safety of L dopa monotherapy and concomitant L dopa therapy with dopamine agonists (bromocriptine or pergolide) of the treatment of Parkinson's disease Methods The clinical trial was performed in the multicentre,open label study L dopa group: 47 cases,L dopa plus bromocriptine group: 43 cases and L dopa plus pergolide group: 48 cases The clinical efficacy was assessed with modified Webster's scale and motor dysfunction rating scale for Parkinson's disease ( MDRSPD ),and safety data included blood hepatic and renal function tests,blood and urine routine tests,arterial blood pressure,heart rate measurements and electrocardiogram were also analyzed at the beginning and end of study The average daily dose of L dopa in levedopa group was (523 3?235 9) mg,The average daily dose of L dopa and bromocriptine were (526 7?241 3) mg and (7 3?1 5) mg in L dopa plus bromocriptine group,respectively The average daily dose of L dopa and pergolide were (558 3?192 9)mg and (0 235?0 045) mg in L dopa plus pergolide group separately Result The clinical improvement was about 74 5%both in assessment of modified Webster's scale and MDRSPD in L dopa group The clinical score was improved in 69 8% (Webster's scale) and 79 1% (MDRSPD) in L dopa plus bromocriptine group,respectively The clinical improved rates were 77 9%( Webster's scale ) and 81 3%( MDRSPD ) in L dopa plus bergolide group The incidence rates of side effects were 27 7%in L dopa group,39 5%in L dopa plus bromocriptine and 18 8%in L dopa plus pergolide groups Conclusion There was an efficacy in treatment of Parkinson's disease in either L dopa monotherapy or combination with bromocriptine or pergolide The treatment of L dopa alone was more effective in the early stage of Parkinson's disease and concomitant L dopa therapy with dopamine agonists were more effective in the advanced stage of Parkinson's disease,pergolide was not only more effective,safe and tolerable,but also fewer adverse events than Bromocriptine was in this short term trial